Qilu Pharmaceutical Company Ltd. — licence , not currently licensed, last inspection rating C (2025-10-23).
No Canadian shortage report is currently matched to this DIN.
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02467496 | APO-CEFEPIME | APOTEX INC | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Marketed |
| 02467518 | APO-CEFEPIME | APOTEX INC | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Marketed |
| 02319020 | CEFEPIME FOR INJECTION | APOTEX INC | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Approved |
| 02499096 | CEFEPIME FOR INJECTION USP | HIKMA CANADA LIMITED | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Marketed |
| 02499088 | CEFEPIME FOR INJECTION USP | HIKMA CANADA LIMITED | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Approved |
| 02464004 | CEFEPIME FOR INJECTION, USP | QILU PHARMACEUTICAL CO., LTD. | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Approved |
| 02319039 | CEFEPIME FOR INJECTION | APOTEX INC | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Dormant |
| 02163632 | MAXIPIME FOR INJECTION -PWS IV IM 1G | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 1 G | Cancelled Post Market |
| 02163640 | MAXIPIME FOR INJECTION-PWS IV 2GM | BRISTOL-MYERS SQUIBB CANADA | Powder For Solution | CEFEPIME (CEFEPIME HYDROCHLORIDE) 2 G | Cancelled Post Market |